Vistin Pharma Asa · OSL:VISTN

Vistin Pharma Asa — Q3 2017 Earnings Presentation

20 slides from Vistin Pharma Asa's earnings presentation, Oct 27, 2017

  1. Slide 1: Vistin Pharma - Third Quarter 2017

    Vistin Pharma - Third Quarter 2017 Kjell-Erik Nordby (CEO) and Gunnar Manum (CFO) 27 October 2017 1

  2. Slide 2: Agenda

    Agenda Highlights Operational review Financial review Summary & outlook Appendix 2

  3. Slide 3: Highlights: Third quarter 2017

    HIGHLIGHTS Third quarter 2017  Revenue growth of 22%, continued strong demand for metformin from Vistin Pharma - Revenue of NOK 46.7 million for the quarter vs. NOK 38.3 million in Q3 2016 - Sales volumes up 31.6% when compared to Q3 2016 - Production running at full capacity  Capacity expansion o

  4. Slide 4: CMO and opioids business sold

    CMO and opioids business sold Summary Revenue (pro forma*) for continuing operations (NOK million)  Sale of CMO and opioids business completed on 2 October 176 171  The sale has allowed Vistin Pharma to propose 149 156 an extraordinary dividend of NOK 7 per share 135 116 - Total distribution to sh

  5. Slide 5: Vistin Pharma has become a pure play metformin company with a bright outlook

    Vistin Pharma has become a pure play metformin company with a bright outlook DIABETES METFORMIN A BRIGHT OUTLOOK - - FOR VISTIN PHARMA ONE OF THE THE GOLD STANDARD - LARGEST HEALTH + TREATMENT OF TYPE = A LEADING GLOBAL EMERGENCIES IN THE 2 DIABETES PRODUCER OF 21ST CENTURY PREMIUM METFORMIN 5

  6. Slide 6: Agenda

    Agenda Highlights Operational review Financial review Summary & outlook Appendix 6

  7. Slide 7: Diabetes – A global emergency

    Diabetes – A global emergency  Diabetes in perspective:  1 in 7 births is affected by gestational diabetes  1 in 11 adults have diabetes  Every 6 seconds a person dies from diabetes Number of people living with diabetes Source International Diabetes Federation, IDF Diabetes Atlas, seventh editio

  8. Slide 8: Running at full capacity

    OPERATIONAL REVIEW Running at full capacity  Sales volume year-to-date 2 300 metric tonnes Sales volume metformin (HCl & DC) (2 170 MT YTD 2016) Metric tonnes per quarter 856  Ongoing efficiency programme to stretch 804 760 production capacity by approx. 300MT 709 704 739 608 611 613  Due to inst

  9. Slide 9: Capacity expansion on track

    OPERATIONAL REVIEW Capacity expansion on track Detailed engineering phase completed, capex estimate reconfirmed Summary  Vistin Pharma not able to meet the current demand from existing and new customers  Strong and stable underlying growth in the metformin market Background  Strong demand for Vi

  10. Slide 10: Agenda

    Agenda Highlights Operational review Financial review Summary & outlook Appendix 10

  11. Slide 11: Key quarterly figures for Vistin Pharma

    HIGHLIGHTS Key quarterly figures for Vistin Pharma (figures for continuing operations) Revenue EBITDA NOK million NOK million 54 47 47 45 43 42 38 33 9* 8 13 9*** 5 5 4 4 1 -1 Q415 Q116 Q216 Q316 Q416 Q117 Q217 Q317 Q415 Q116 Q216 Q316 Q416 Q117 Q217 Q317 -2** Adjusted EBITDA One-off items *NOK 8.8

  12. Slide 12: Consolidated income statement

    FINANCIAL REVIEW Consolidated income statement (NOK 1 000) Q3 2017 Q3 2016 YTD 2017 YTD2016 FY 2016 Total revenue and income 46 725 39 329 144 225 140 791 173 261 EBITDA 4 265 5 149 21 806 26 726 24 020 Adjustments relating to specific items: Costs relating to reactor break-down - - - - 1 702 Net ef

  13. Slide 13: Financial position

    FINANCIAL REVIEW Financial position (NOK 1 000) 30.09.2017 30.09.2016 31.12.2016 Property, plant & equipment 57 434 46 202 53 552 Inventory 24 025 86 711 79 316 Trade receivables 64 264 57 005 45 365 Cash & cash equivalents 33 524 72 709 89 440 Other 93 107 8 416 11 844 Total Assets 272 355 271 043

  14. Slide 14: Agenda

    Agenda Highlights Operational review Financial review Summary & outlook Appendix 14

  15. Slide 15: Summary & outlook

    Summary & outlook Transforming to a pure play metformin player  Metformin market expected to continue to grow - Diabetes one of the largest health emergencies in the 21st century - Metformin expected to maintain position as the Gold Standard treatment for T2D in the foreseeable future  Strong dema

  16. Slide 16: Agenda

    Agenda Highlights Operational review Financial review Summary & outlook Appendix 16

  17. Slide 17: Top 20 shareholders as of 19 October 2017

    Top 20 shareholders as of 19 October 2017 NAME SHAREHOLDING % SHARE STATE STREET BANK 2 348 717 13,77 % STRATA MARINE & OFFSHORE* 1 965 943 11,53 % STOREBRAND VEKST 1 245 828 7,30 % MP PENSJON 877 870 5,15 % SKANDINAVISKE ENSKILDA 839 352 4,92 % HOLMEN SPESIALFOND 800 000 4,69 % NORDEA 599 489 3,52

  18. Slide 18: Experienced management team

    Experienced management team Name Role Experience  Previous experience includes several years in top management positions at Alpharma, Chief Executive a leading international generic pharmaceutical company Kjell-Erik Nordby Officer  Holds a Master's degree in Pharmacy and Master's degree in Busines

  19. Slide 19: Board of Directors

    APPENDIX Board of Directors* Ole Enger Chairman Mr Enger has extensive industrial experience and is currently the Chairman of the Board of REC Solar ASA. Enger was previously the CEO of REC ASA, a position held from April 2009. Prior to REC ASA, Enger was the president & CEO of SAPA AB, and he has a

  20. Slide 20: Thank you for your attention!

    Thank you for your attention! www.vistin.com 20

Vistin Pharma — Q3 2017 Earnings Presentation on 6ix